WHO Calls for Greater Action to Eliminate Hepatitis
The regimen posted 93.9% sustained virologic response in 905 patients, nearly matching Epclusa and supporting a shorter treatment course, Atea said.
- On Tuesday, July 28, 2026, Atea Pharmaceuticals announced positive topline results from C-BEYOND, its pivotal Phase 3 trial evaluating bemnifosbuvir and ruzasvir for chronic hepatitis C virus, coinciding with World Hepatitis Day.
- Roughly 4 million people in the U.S. live with chronic HCV, a condition that can progress to cirrhosis, end-stage liver disease, or liver cancer if left untreated, creating urgent demand for effective treatments.
- The trial achieved its primary endpoint of statistical non-inferiority, with BEM/RZR demonstrating a 93.9% sustained virologic response rate versus 94.8% for SOF/VEL in the mITT population of 905 patients.
- Clinical Professor Dr. Eric Lawitz of the Texas Liver Institute called the 8-week regimen a "meaningful step forward" for HCV care, noting it could streamline prescribing and accelerate test-and-treat strategies.
- Atea expects to share results from C-FORWARD, its second Phase 3 trial, in early 2027, while the World Health Organization aims to reduce new hepatitis infections to just over 500,000 annually by 2030.
23 Articles
23 Articles
For two consecutive years, Brazil has achieved goals to eliminate mother-to-child transmission of hepatitis B. Less than 0.1% of children up to five years of age had active virus infection in the country, which meets the certification criteria of the Pan-American Health Organization (PAHO) and the World Health Organization (WHO). The request for receipt was made on Tuesday (28). With delivery, the request will be submitted to the internal evalua…
Tanzania Cuts Hepatitis Burden
DAR ES SALAAM -- AS Tanzania marked World Hepatitis Day yesterday, the latest statistics showed the country's viral hepatitis burden has declined, reinforcing government efforts to eliminate the disease as a public health threat by 2030.
On the occasion of the World Hepatitis Day on 28 July, the Wiener Gesundheitsverbund draws attention to the importance of vaccination, early detection and treatment of viral hepatitis. Austria and the world are struggling with a massive liver problem. Every 30 seconds, a human being dies from chronic virus-related hepatitis. The situation is also serious in this country: 25 to 30 percent of Austrians are affected by fatty liver disease according…
More than 845 new cases of hepatitis A were reported in 2025, a growth of 265% compared to 2024. The increase is associated with person-to-person transmission and sexual contact.
Coverage Details
Bias Distribution
- 50% of the sources lean Right
Factuality
To view factuality data please Upgrade to Premium
